Baveno VII再代偿标准在恩替卡韦治疗的乙型肝炎相关失代偿期肝硬化患者中的验证
多中心前瞻性研究纳入320例乙型肝炎相关失代偿期(腹水)肝硬化患者,恩替卡韦治疗120周。283例完成研究,261/283(92.2%)HBV DNA<20 IU/ml,171/283(60.4%)腹水消退、脑病缓解且至少12个月无复发性静脉曲张出血。以MELD<10和/或肝功能属Child-Pugh A级(白蛋白>35 g/L、INR<1.50、总胆红素<34 μmol/L)为肝功能稳定改善标准,56.2%(159/283)符合Baveno VII再代偿定义。
要点
- 恩替卡韦治疗120周后,261/283(92.2%)患者HBV DNA<20 IU/ml。
- 171/283(60.4%)患者腹水消退、脑病缓解且至少12个月无复发性静脉曲张出血。
- 以MELD<10和/或Child-Pugh A级肝功能为稳定改善标准,56.2%(159/283)符合Baveno VII再代偿定义。
核心结论
- 本研究定义了CHB相关失代偿期肝硬化抗病毒治疗患者满足Baveno VII再代偿定义所需的肝功能稳定改善标准。
- 该多中心前瞻性研究得出的标准需在其他病因肝硬化患者中进一步验证。
研究设计与样本
- 多中心前瞻性研究,纳入失代偿(腹水)CHB相关肝硬化患者,恩替卡韦治疗120周,每6个月随访临床事件、病毒学与生化检查及超声。
- 共招募320例患者,283例完成120周研究。
主要发现
- 283例完成研究中,261/283(92.2%)达到HBV DNA<20 IU/ml。
- 171/283(60.4%)达到腹水消退、脑病缓解且至少12个月无复发性静脉曲张出血。
- 以MELD<10和/或肝功能属Child-Pugh A级(白蛋白>35 g/L、INR<1.50、总胆红素<34 μmol/L)为肝功能稳定改善标准时,56.2%(159/283)符合Baveno VII再代偿定义。
关键数值与推荐
- 肝功能稳定改善标准:MELD<10和/或肝功能属Child-Pugh A级(白蛋白>35 g/L、INR<1.50、总胆红素<34 μmol/L)。
- Baveno VII再代偿定义在本研究标准下于56.2%(159/283)患者中满足。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本研究得出的标准需在其他病因肝硬化患者中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Antiviral therapy improves the clinical outcomes of patients with chronic hepatitis B (CHB), including those with cirrhosis. In the present study, we validated the Baveno VII definition of recompensation and explored the criteria for stable improvement of liver function tests in entecavir-treated patients with CHB-related decompensated cirrhosis. METHODS: In this multicentre prospective study, patients with decompensated (ascites) CHB-related cirrhosis were enrolled and treated with entecavir for 120 weeks. Patients were followed up for clinical events, viral and biochemical tests, and ultrasonography every 6 months. The recompensation rate per Baveno VII criteria was calculated. Multivariate regression models were used to identify the predictors of recompensation. Finally, the criteria for stable improvement of liver function tests were explored. RESULTS: Of the 320 recruited patients, 283 completed the 120-week study, with 261/283 (92.2%) achieving HBV DNA levels <20 IU/ml and 171/283 (60.4%) achieving resolution of ascites, encephalopathy, and absence of recurrent variceal bleeding for at least 12 months. We identified model for end-stage liver disease <10 and/or liver function tests within Child-Pugh Class A (albumin >35 g/L, international normalised ratio <1.50 and total bilirubin <34 μmol/L) as the criteria for stable improvement of liver function tests. Accordingly, 56.2% (159/283) of patients fulfilled the Baveno VII definition of recompensation with a stable improvement of liver function tests defined by the current study. CONCLUSIONS: Our study defined the criteria for a stable improvement of liver function tests required by the Baveno VII definition of recompensation in patients with CHB-related decompensated cirrhosis on antiviral therapy. The criteria derived from this multicentre prospective study warrant further validation in patients with cirrhosis of other aetiologies. LAY SUMMARY: Decompensation of cirrhosis marks the point at which the liver is no longer able to function normally (and symptoms become apparent). Recently the idea of recompensation was proposed for individuals who may experience an improvement in liver function if the underlying cause of their liver disease is addressed (e.g. antivirals for viral cirrhosis). Herein, we show that over 50% of patients with hepatitis B-related decompensated cirrhosis treated with antivirals could recompensate and we propose laboratory criteria which could be used to define recompensation.
引用
- Wang Q, Zhao H, Deng Y, et al. Validation of Baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis. J Hepatol. 2022. PMID: 36038017. doi:10.1016/j.jhep.2022.07.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。